Glenmark Pharmaceuticals Inc., USA announced today the launch of Latanoprost Ophthalmic Solution, 0.005 per cent, a generic version of Upjohn’s Xalatan. This marks the company’s fourth ophthalmic product entry, targeting a market that generated approximately $113.5 million in annual sales for the 12-month period ending December 2024, according to IQVIA data.
The shares of Glenmark Pharmaceuticals Limited were trading at ₹1,345.30 down by ₹65.90 or 4.67 per cent on the NSE today at 11.30pm.
The solution is bioequivalent and therapeutically equivalent to the reference listed drug and will be available through the same ophthalmic channels as the company’s existing eye care portfolio.
Marc Kikuchi, President & Business Head, North America, stated that this launch “highlights our commitment to meeting market needs and providing quality solutions for our customers” in the ophthalmic segment.
Glenmark Pharmaceuticals Ltd. operates across 80 countries with 11 manufacturing facilities on four continents. The company, which ranks among the top 100 biopharmaceutical companies by pharmaceutical sales according to Scrip 100, focuses on respiratory, dermatology, and oncology therapeutics. In 2023, Glenmark became the second pharmaceutical company in India to have its greenhouse gas emission reduction targets approved by the Science Based Target initiative.